The European market for vascular access devices will see slight growth over the forecast period, driven in large part by the rising adoption of PICCs in all European countries, as well as the rising adoption of new technologies such as power-injectable devices, and devices with antimicrobial coatings. However, market revenues will be hindered to some extent by declining ASPs resulting from pricing pressures and increasing competition. Importantly, the impact of the COVID-19 pandemic on procedures, unit sales, and revenues has been incorporated into the market projections.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for vascular access devices in Europe across a 10-year period.
The COVID-19 global pandemic will have a dual effect on the vascular access market in the short term.
How will trends change in different vascular access device segments as a consequence of COVID-19?
What factors contribute to the market changes?
What plans are being executed by manufacturers in response to the pandemic?
Companies have developed innovative products designed to reduce the likeliness of catheter-related BSIs and clot formation.
How will the various vascular access device markets be affected by the introduction of novel technologies?
What innovative products have companies introduced in Europe to cater to this unmet need? How will these products be adopted over the forecast period?
Which regions will see stronger adoption of these innovative devices and which regions will experience restricted growth?
How will clinical trials examining the incidence of DVT among vascular access patients impact the market?
The PICC segment will see rapid growth in Europe.
How does the adoption of PICCs vary between countries and what factors are responsible for these differences?
How will the rapid adoption of PICCs affect other vascular access device segments?
Power-injectable devices will account for a large and growing proportion of the market.
Which segments will see the highest adoption of power-injectable devices?
What advantage does power-injectability provide and what role it will play in the growth of vascular access device market?
- Vascular Access Devices - Market Insights - Europe
Author(s): Jackie Liu
Jackie Liu is an analyst within the Cardiovascular Medtech Insights team at DRG (Part of Clarivate), specializing in peripheral vascular device markets. Jackie holds a PhD in Molecular Genetics and a MPH in Epidemiology from the University of Toronto. Prior to her current position, Jackie worked at multiple public health organizations in Ontario, gaining extensive experience with reporting and analyzing large-scale health data.